Atomoxetine Hydrochloride
Atomoxetine is a selective norepinephrine reuptake inhibitor used in the treatment of attention-deficit/hyperactivity disorder (ADHD) It is not a psychostimulant and is not an amphetamine derivative.Treatment of attention-deficit/hyperactivity disorder (ADHD) in childen 6 years of age and older, adolescents and adults.
Children and adolescents upto 70 kg body weight: Total daily dose of approximately 0.5mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2mg/kg administered either as a single daily dose in the morning or as evenly divided doses in he morning and late afternoon/early evening. Children and adolescents over 70 kg body weight and adults: Total daily dose of 40mg and increased after a minimum of 3 days to a target total daily dose of approximately 80mg ad
Hypersensitivity narrow angle glaucoma. Treatment with an MAOI should not be initiated within 2 weeks after discontinuing atomoxetine.
It should be used with caution in patients with hypertension, tachycardia or cardiovascular or cerebrovascular disease. Pulse and blood pressure should be measured periodically. It should be used with caution in patients predisposed to hypotension. Growth should be monitored during treatment.Patients should use caution when driving or operating machinery.Pregnancy & Lactation.
-Common: Dry mouth, nausea, decreased appetite, insomnia, and fatigue. -Serious: Increased heart rate, hypertension, liver damage, and severe allergic reactions.
-May interact with MAOIs, which can lead to serious, potentially life-threatening reactions. -Caution with drugs affecting the CYP2D6 enzyme system (e.g., some antidepressants, antipsychotics). -Potential interactions with drugs that affect cardiovascular function.
